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BACkgROunD AnD OBjECtIvEs: plasmablastic lymphoma is a recently described b-cell derived lymphoma. 
the prognosis of plasmablastic lymphoma patients is usually poor. We performed a systematic review of the 
literature on the use of highly active anti-retroviral therapy (haart) and the prognosis of plasmablastic lym-
phoma. 
MEthODs: a comprehensive search of relevant databases, including medline, embase, the cochrane controlled 
trials register, the cochrane library, and the science citation index yielded ten randomized controlled trials. 
trials were divided into two groups according to therapy. the rates of plasmablastic lymphoma were analyzed 
using a fixed-effects model. sensitivity analyses (on publication type, statistical model) were performed to further 
detect and evaluate clinically significant heterogeneity. tests of survival for plasmablastic lymphoma were also 
performed by using Kaplan-meier method. 
REsuLts: meta-analysis result showed that the prognosis of plasmablastic lymphoma patients was statistically 
different in the patients receiving haart in addition to chemotherapy and/or radiotherapy than in the patients 
receiving the chemotherapy and/or radiotherapy alone (pooled relative risk=3.04; P=.03). survival analyses also 
displayed a statistically significant difference (c2=6.22, P=.013). 
COnCLusIOn: haart in addition to chemotherapy and/or radiotherapy is effective in improving the prognosis 
of plasmablastic lymphoma. however, the small sample sizes increase the likelihood of bias in the studies in this 
meta-analysis, and therefore, the results should be taken cautiously. 
Plasmablastic lymphoma (PBL) is a rare variant of a diffuse, large B-cell lymphoma, which typically presents in the oral cavity in immunodeficient 
patients.1 More recently, the World Health Organization 
(WHO) has classified PBL, accepted as a new entity in 
the WHO classification of tumors of the hematolpoi-
etic lymphoid tissues (4th edition), as an AIDS-related 
illness. According to the definition of WHO, PBL is 
a diffuse proliferation of large neoplastic cells, most of 
which similar to B immunoblasts, but in which all tu-
mor cells have the immunophenotype of plasma cells 
(CD138 and VS38c positive).2-4 PBL accounts for ap-
proximately 2.6% of all HIV-related non-Hodgkin lym-
phomas (NHL).5 About 76% of PBLs are reported to be 
infected by EBV and 17% to 37% by Kaposi sarcoma-
associated herpesvirus (HHV8).1,6-8 
The prognosis of PBL patients is usually poor, re-
gardless of the site of origin, and the factors influenc-
ing prognosis are not clear. The clinical course is very 
aggressive with most of patients dying in the first year 
after diagnosis.7,9 After a review of the literature, we 
concluded that highly active anti-retrovirus therapy 
(HAART) might be an important influencing factor 
on the prognosis of PBL. Therefore, we performed a 
meta-analysis to assess the effects of HAART on the 
prognosis of PBL. 
MEthODs 
Only randomized controlled trials (RCTs) on the prog-
nosis of PBL that included patients receiving treatment 
with HAART were eligible for inclusion in this study. 
All patients had to be diagnosed as having PBL con-
firmed by pathology, including some variants of PBL 
who were HIV negative. Patients with other variants 
original research report HaarT  meTa-analYSiS
Hematol Oncol Stem Cell Ther 3(1)     First Quarter 2010 hemoncstem.edmgr.com8
of diffuse large B-cell lymphoma with plasmablastic fea-
tures were not included in this study. Inclusion criteria 
for each study in the main analysis were: (1)a minimal 
clinical follow-up of 24 hours; (2) a minimum sample 
size of 2 per trial; (3) patients receiving chemotherapy 
and/or radiotherapy and/or HAART; (4) comparison 
patients not receiving HAART or patients receiving che-
motherapy and/or radiotherapy alone. 
We used the following sources for the identification 
of trials: the Cochrane Central Register of Controlled 
Trials, the Cochrane Library, PubMed, Embase, Science 
Citation Index and meeting abstracts, up to December 
2008. Key words were ‘plasmablastic lymphoma’, ‘plas-
mablastic lymphomas’, ‘highly active anti-retrovirous 
therapy’, ‘HAART’. The search terms were MeSH terms 
and the search was limited to RCTs in English. Two re-
viewers (Guan and Zhou) independently checked the 
titles, abstract sections and keywords of every record re-
trieved. Full articles were retrieved for further assessment 
when the information suggested the studies were eligible. 
References in papers identified in the electronic search 
were manually searched for relevant trials not included 
in electronic databases. Each was imported into a bib-
liographic database EndNote (Version X1) and merged 
into one core database. The contents of that database 
were exported to the computer program Review Manager 
(Version 5.0 for Windows; the Cochrane Collaboration, 
Oxford, UK, http://www.cc-ims.net/revman). 
Two reviewers extracted data on intervention and out-
comes independently, using a pre-tested data extraction 
form that was adapted from a standard form provided 
by the review group. The data extraction form included 
general information, study characteristics, information 
on participants, interventions, baseline characteristics 
and measurements and outcomes. Differences in data ex-
traction were resolved by consensus, referring back to the 
original article. If necessary, information was sought from 
the authors of the original studies. The included studies 
were divided into two groups according to whether they 
received chemotherapy or radiotherapy or HAART vs. 
non-therapy (subgroup 1), and to whether they received 
HAART in addition to chemotherapy and/or radio-
therapy vs. receiving chemotherapy and/or radiotherapy 
alone (subgroup 2). 
Assessment of each trail was performed by two inves-
tigators (Guan and Zhou) independently. Disagreement 
was resolved by discussion between the two reviewers 
with consensus or with consultation of a third reviewer 
(Zhang). In particular, the following quality criteria were 
assessed: randomization procedure, allocation conceal-
ment, method of blinding, handling of drop-outs (inten-
tion-to-treat analysis), quantity of dropouts, selective Figure 1. Study flow diagram of included and excluded studies. 
(skewed) dropout, and method of blinding outcome 
assessment (if applicable). Quality of the trials were as-
sessed by the Jadad quality scale,12,13 a composite scoring 
system that includes randomization, concealment, and 
patient withdrawal and dropout. Trials with a score ≥3 
were considered of high quality. 
Dichotomous data were expressed as odds ratios (OR) 
or risk ratio (RR). Heterogeneity among the studies was 
examined using the DLQ statistic.10 Pooled OR, RR and 
95% confidence interval (CI) was calculated using the 
Mantel-Haenszel fixed-effects model when no statisti-
cally significant heterogeneity was detected. A random 
effects model was employed using the DerSimonian and 
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Laird (DL) method if there was statistically significant 
heterogeneity. The chi-square statistic was set at a=0.1, 
with P<.1 indicating a statistically significant difference. 
The Z score was set at a=0.05, with P<.05 indicating a 
statistically significant difference. 
Publication bias was estimated by examining the re-
lationship between the treatment effects and the stan-
dard error of the estimate (S.E log RR) using a funnel 
plots. Quantification of the effect of heterogeneity would 
be assessed by means of I squared, ranging from 0% to 
100% including its 95% confidence interval (CI) with 
significance set at P>50%.11 I-squared demonstrates the 
percentage of total variation across studies due to het-
erogeneity and was used to judge the consistency of evi-
dence. The analyses were done with the Review Manager 
(Version 5.0 for Windows; the Cochrane Collaboration, 
Oxford, UK, http://www.cc-ims.net/revman).The statis-
tically significant differences in each control group be-
tween subgroups were analyzed using the chi-square test, 
with P<.05 indicating statistically differences. Test of 
survival for HAART on the prognosis of PBL were also 
performed by using Kaplan-Meier method, with P<.05 
indicating statistically significant differences. The date 
were processed by use of SPSS 16.0 (SPSS, Chicago, 
IL). 
Several sensitivity analyses were performed to inves-
tigate the possible influence of the predefined quality 
criteria, including the statistical model (random-effects 
vs. fixed-effects). OR values were calculated for the sensi-
tivity analyses. Several methods were employed to assess 
sensitivity. The effect of publication type was examined 
by excluding trials published in the form of abstracts 
only. The effect of study quality was examined by exclud-
ing trials with a Jadad score <3. The effect of sample size 
was examined by excluding trials with sample size <2. 
REsuLts 
A total of 88 studies were retrieved (Figure 1). Of these, 
25 were irrelevant and excluded and 46 were excluded 
because they were only case reports. Seven studies were 
excluded because of poor data ( Jadad score <3). Ten 
studies were included in our analysis (Table 1).1,7,14-19 
Subgroup 1 included eight trials. Subgroup 2 included 
two trials. A funnel plots suggested there was no publica-
tion bias (Figure 2). 
Primary outcomes 
Ten studies on PBL involving 93 patients were identified. 
No statistically significant heterogeneity existed in either 
subgroup 1 (P=.44) (Figure 3) or in subgroup 2 (P=.18) 
(Figure 4). In subgroup 1, the results showed no statis-
tically significant differences in the patients receiving 
Table 1. Characteristics of  the 10 studies  in the  meta-analysis. 
   Study Sample size Research design Jadad Score 
   Subgroup 1 
      Chetty 200314 4 Unclear 3 
      Cioc200415 4 Unclear 3 
      Delecluse 19971  16 rCT 4 
      Dong 20057 14 rCT 3 
      Folk 200616 5 rCT 3 
      gaidano 200217 12 rCT 4 
      reidal 200818 5 rCT 3 
      Teruya-Feldstein 200519 12 rCT 4 
   Subgroup 2 
      gaidano 200217 10 rCTs 4 
      Teruya-feldstein 200519 11 rCTs 4 
Subgroup 1: Chemotherapy or radiotherapy or HaarT vs. no therapy 
Subgroup 2: HaarT in addition to chemotherapy and/or radiotherapy vs. chemotherapy and/or radiotherapy alone. 
methodological quality: all studies were double-blinded; drop-out rates and randomization methods were clearly 
reported, but allocation concealment was unclear in every report. 
Figure 2. Funnel plot for the detection of publication bias for subgroups indicating no 
publication bias (broken lines are 95% confidence limits).
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chemotherapy or radiotherapy or HAART than in the 
patients receiving non-therapy (30.2%, 16/53 vs. 5.3%, 
1/19; pooled RR=1.87; 95% CI: 0.90-3.87; P=.09) on 
the prognosis of PBL. In subgroup 2, the results indi-
cated statistically significant differences in patients re-
ceiving HAART in addition to chemotherapy and/or 
radiotherapy compared with patients receiving chemo-
therapy and/or radiotherapy alone (75%, 6/8 vs. 23.1%, 
3/13; pooled RR=3.04; 95% CI: 1.09-8.45; P=.03) on 
the prognosis of PBL. No statistically significant differ-
ences were detected in the prognosis of PBL between 
the controls in either subgroup (5.26%, 1/19 vs. 23.08, 
3/13%, c2=1.70, P=.19). 
Sensitivity analyses 
We selected a random-effects model for the analysis. 
Figure 3. Forest plot for results in subgroup 1 studies, indicating no statistically significant differences between chemotherapy or 
radiotherapy or HaarT vs non-therapy (size of data points represents sample size of study). 
Figure 4. Forest plots for results of meta-analysis in subgroup 2 studies, indicating statistically significant differences for HaarT in 
addition to chemotherapy and/or radiotherapy vs chemotherapy and/or radiotherapy alone (size of data points represents sample size 
of study). 
Overall, the estimates of effect on prognosis of PBL 
were virtually identical for the sensitivity analyses and 
the meta-analysis (Table 2). 
Survival analyses 
Survival analyses were performed for the comparison 
of HAART in addition to chemotherapy and/or radio-
therapy vs. the chemotherapy and/or radiotherapy alone, 
and for the comparison of HIV-infected vs. non-HIV 
infected patients. In the comparison of HAART, sta-
tistically significant differences on the prognosis of PBL 
were detected between the patients receiving HAART 
in addition to chemotherapy and/or radiotherapy and 
the patients receiving the chemotherapy and/or radio-
therapy only (c2=6.22, degree of freedom=1, P=.013, 
log rank test with two-sided P values) (Figure 5). In the 
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Table 2. Sensitivity analysis for the possible influence of the predefined quality criteria.
   Method Subgroup Patients OR (95%CI) Z P 
Heterogeneity 
c2 P I2 
   Full text of publication 
Subgroup 1 72 2.52 (0.78, 8.16) 1.54 0.12 5 0.73 0% 
Subgroup 2 21 8.91 (1.16, 68.54) 2.1 0.04 0.82 0.37 0% 
   random-effect model 
Subgroup 1 72 2.52 (0.68, 9.30) 1.38 0.17 5 0.66 0% 
Subgroup 2 21 8.67 (1.03, 73.20) 1.98 0.05 0.82 0.37 0% 
   Total Events   93 3.49 (1.27, 9.59) 2.43 0.02 6.76 0.66 0% 
Figure 5. Kaplan-meier survival analysis plots showing statistically significant 
differences between intervention groups and controls (c2=6.22, degree of freedom=1, 
P=.013, log rank test with two-sided P values). 
comparison of HIV vs non-HIV patients, no statistical-
ly significant differences was detected in the prognosis of 
PBL (c2=2.49, degree of freedom=1, P=.114, log rank 
test with two-sided P values). 
DIsCussIOn 
The factors influencing the prognosis of PBL are not 
clear. Castillo et al20 studied 112 published cases and 
found that EBV status, primary site of involvement, and 
clinical stage failed to show an association with survival 
using log-rank tests with two-sided P values. However, 
he did not perform a meta-analysis. On the other hand, 
there is no unified and effective agreement on the therapy 
for PBL.18 Therapy depends on the clinical stage and the 
clinical symptoms caused by HIV infection. Moreover, 
there is no information on how choice of therapy relates 
to prognosis of PBL.18,20-23 To clarify this question, we 
used the Cochrane systematic review method. 
Our meta-analysis showed that HAART combined 
with chemotherapy and/or radiotherapy was more ef-
fective in improving the prognosis of PBL patients than 
chemotherapy and/or radiotherapy alone. However, 
The 95% CIs in some studies were very wide and the 
sample sizes small, which indicates a lack of precision in 
the estimate of relative risk. The small sizes of the trials 
might introduce bias in the results of the meta-analysis. 
There might also be a language bias, since only trials re-
ported in English were included. The significant results 
in the survival analyses support the hypothesis that the 
addition of HAART to therapy has a favorable effect 
on prognosis, but the limitations associated with retro-
spectively accumulated data make it hard to draw firm 
conclusions. Therefore, the results should be interpreted 
cautiously. Larger, prospective studies are needed to fur-
ther elucidate survival advantages for treatment that in-
cludes HAART. 
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